Correction: Circulating Ang-2 Mrna expression levels: Looking ahead to a new prognostic factor for NSCLC (PLoS ONE (2014) 9, 2 (e90009) DOI: 10.1371/journal.pone.0090009);Circulating ang-2 mrna expression levels: Looking ahead to a new prognostic factor for NSCLC

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Coelho, Ana L ^a,b   Araú Jo, Antonio ^a,c,d   Gomes, Monica ^a,d   Catarino, Raquel ^a,d   Marques, Agostinho ^b,e   Medeiros, Rui ^a,d,f  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c Centro Hospitalar de Entre O Douro e Vouga   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e Centro Hospitalar Universitário de São João   (Portugal)

^f Portuguese League Against Cancer (Norte)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; MESSENGER RNA;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SMOKING;

AGED; ANGIOPOIETIN-2; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896532455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097979     Document Type: Erratum

References (28)

1. Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382: 720-731.
2. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of nonsmall-cell lung cancer: recent developments. Lancet 382: 709-719.
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
4. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, et al. (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
5. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE (2013) Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73: 1649-1657.
6. Fagiani E, Christofori G (2013) Angiopoietins in angiogenesis. Cancer Lett 328: 18-26.
7. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, et al. (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
8. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, et al. (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005.
9. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, et al. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy. Clin Cancer Res.
10. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
11. Andersen S, Donnem T, Al-Shibli K, Al-Saad S, Stenvold H, et al. (2011) Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One 6: e19773.
12. Naumnik W, Chyczewska E, Ossolinska M (2009) Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy. Cancer Invest 27: 741-746.
13. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013) Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 788: 341-348.
14. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, et al. (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132: 200-206.
15. Takanami I (2004) Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep 12: 849-853.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
17. Livak KJ, and Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 25:402-408 (Pubitemid 34164012)
18. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, et al. (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12: 201-210.
19. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, et al. (2011) Non-small-cell lung cancer. Lancet 378: 1727-1740.
20. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, et al. (2011) Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res 30: 115.
21. Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31: 1039-1049.
22. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
23. Lammers PE, Horn L (2013) Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw 11: 1235-1247.
24. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, et al. (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937.
25. Thomas M, Kienast Y, Scheuer W, Bahner M, Kaluza K, et al. (2013) A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One 8: e54923.
26. KP P, NG C, A P, L A, AS L, et al. (2011) A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology 29.
27. Palmer GM, Tiran Z, Zhou Z, Capozzi ME, Park W, et al. (2012) A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 165: 1891-1903.
28. Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, et al. (2011) A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 18: 598-607.